Literature DB >> 31866263

Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States.

Hasan Khosravi1, Sophia Zhang2, Alyce M Anderson3, Laura K Ferris4, Sonal Choudhary3, Timothy Patton3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31866263     DOI： 10.1016/j.jaad.2019.12.034

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  1 in total

1.  Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Authors:  Lotte S Spekhorst; Lieneke F M Ariëns; Jorien van der Schaft; Daphne S Bakker; Marijke Kamsteeg; Albert J Oosting; Ilona de Ridder; Annemiek Sloeserwij; Geertruida L E Romeijn; Marlies de Graaf; Inge Haeck; Judith L Thijs; Marie L A Schuttelaar; Marjolein S de Bruin-Weller
Journal:  Allergy       Date:  2020-05-05       Impact factor: 13.146
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.